GSK and Theravance submit Anoro to FDA as COPD drug

02/20/2013 | American City Business Journals

GlaxoSmithKline and Theravance said the FDA has accepted their new drug application for Anoro as a daily treatment for chronic obstructive pulmonary disease. Anoro, formerly known as UMEC/VI, is a combination of umeclidinium bromide, a long-acting muscarinic antagonist, and vilanterol, a long-acting beta-2 agonist. The FDA is expected to decide by Dec. 18.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN